197 related articles for article (PubMed ID: 24810056)
1. The combination of the prodrugs perforin-CEBPD and perforin-granzyme B efficiently enhances the activation of caspase signaling and kills prostate cancer.
Chuang CH; Wang WJ; Li CF; Ko CY; Chou YH; Chuu CP; Cheng TL; Wang JM
Cell Death Dis; 2014 May; 5(5):e1220. PubMed ID: 24810056
[TBL] [Abstract][Full Text] [Related]
2. HMDB and 5-AzadC Combination Reverses Tumor Suppressor CCAAT/Enhancer-Binding Protein Delta to Strengthen the Death of Liver Cancer Cells.
Li CF; Tsai HH; Ko CY; Pan YC; Yen CJ; Lai HY; Yuh CH; Wu WC; Wang JM
Mol Cancer Ther; 2015 Nov; 14(11):2623-33. PubMed ID: 26358750
[TBL] [Abstract][Full Text] [Related]
3. Epigenetic silencing of CCAAT/enhancer-binding protein delta activity by YY1/polycomb group/DNA methyltransferase complex.
Ko CY; Hsu HC; Shen MR; Chang WC; Wang JM
J Biol Chem; 2008 Nov; 283(45):30919-32. PubMed ID: 18753137
[TBL] [Abstract][Full Text] [Related]
4. CEBPD reverses RB/E2F1-mediated gene repression and participates in HMDB-induced apoptosis of cancer cells.
Pan YC; Li CF; Ko CY; Pan MH; Chen PJ; Tseng JT; Wu WC; Chang WC; Huang AM; Sterneck E; Wang JM
Clin Cancer Res; 2010 Dec; 16(23):5770-80. PubMed ID: 20971808
[TBL] [Abstract][Full Text] [Related]
5. Polycomb- and Methylation-Independent Roles of EZH2 as a Transcription Activator.
Kim J; Lee Y; Lu X; Song B; Fong KW; Cao Q; Licht JD; Zhao JC; Yu J
Cell Rep; 2018 Dec; 25(10):2808-2820.e4. PubMed ID: 30517868
[TBL] [Abstract][Full Text] [Related]
6. RUNX1, an androgen- and EZH2-regulated gene, has differential roles in AR-dependent and -independent prostate cancer.
Takayama K; Suzuki T; Tsutsumi S; Fujimura T; Urano T; Takahashi S; Homma Y; Aburatani H; Inoue S
Oncotarget; 2015 Feb; 6(4):2263-76. PubMed ID: 25537508
[TBL] [Abstract][Full Text] [Related]
7. Polycomb group proteins EZH2 and EED directly regulate androgen receptor in advanced prostate cancer.
Liu Q; Wang G; Li Q; Jiang W; Kim JS; Wang R; Zhu S; Wang X; Yan L; Yi Y; Zhang L; Meng Q; Li C; Zhao D; Qiao Y; Li Y; Gursel DB; Chinnaiyan AM; Chen K; Cao Q
Int J Cancer; 2019 Jul; 145(2):415-426. PubMed ID: 30628724
[TBL] [Abstract][Full Text] [Related]
8. Reciprocal feedback regulation of PI3K and androgen receptor signaling in PTEN-deficient prostate cancer.
Carver BS; Chapinski C; Wongvipat J; Hieronymus H; Chen Y; Chandarlapaty S; Arora VK; Le C; Koutcher J; Scher H; Scardino PT; Rosen N; Sawyers CL
Cancer Cell; 2011 May; 19(5):575-86. PubMed ID: 21575859
[TBL] [Abstract][Full Text] [Related]
9. Androgens suppress EZH2 expression via retinoblastoma (RB) and p130-dependent pathways: a potential mechanism of androgen-refractory progression of prostate cancer.
Bohrer LR; Chen S; Hallstrom TC; Huang H
Endocrinology; 2010 Nov; 151(11):5136-45. PubMed ID: 20881251
[TBL] [Abstract][Full Text] [Related]
10. Activation of EZH2 and SUZ12 Regulated by E2F1 Predicts the Disease Progression and Aggressive Characteristics of Bladder Cancer.
Lee SR; Roh YG; Kim SK; Lee JS; Seol SY; Lee HH; Kim WT; Kim WJ; Heo J; Cha HJ; Kang TH; Chung JW; Chu IS; Leem SH
Clin Cancer Res; 2015 Dec; 21(23):5391-403. PubMed ID: 26268246
[TBL] [Abstract][Full Text] [Related]
11. Down-regulation of human DAB2IP gene expression mediated by polycomb Ezh2 complex and histone deacetylase in prostate cancer.
Chen H; Tu SW; Hsieh JT
J Biol Chem; 2005 Jun; 280(23):22437-44. PubMed ID: 15817459
[TBL] [Abstract][Full Text] [Related]
12. MicroRNA-101 negatively regulates Ezh2 and its expression is modulated by androgen receptor and HIF-1alpha/HIF-1beta.
Cao P; Deng Z; Wan M; Huang W; Cramer SD; Xu J; Lei M; Sui G
Mol Cancer; 2010 May; 9():108. PubMed ID: 20478051
[TBL] [Abstract][Full Text] [Related]
13. miR-124 and Androgen Receptor Signaling Inhibitors Repress Prostate Cancer Growth by Downregulating Androgen Receptor Splice Variants, EZH2, and Src.
Shi XB; Ma AH; Xue L; Li M; Nguyen HG; Yang JC; Tepper CG; Gandour-Edwards R; Evans CP; Kung HJ; deVere White RW
Cancer Res; 2015 Dec; 75(24):5309-17. PubMed ID: 26573802
[TBL] [Abstract][Full Text] [Related]
14. EZH2 oncogenic activity in castration-resistant prostate cancer cells is Polycomb-independent.
Xu K; Wu ZJ; Groner AC; He HH; Cai C; Lis RT; Wu X; Stack EC; Loda M; Liu T; Xu H; Cato L; Thornton JE; Gregory RI; Morrissey C; Vessella RL; Montironi R; Magi-Galluzzi C; Kantoff PW; Balk SP; Liu XS; Brown M
Science; 2012 Dec; 338(6113):1465-9. PubMed ID: 23239736
[TBL] [Abstract][Full Text] [Related]
15. PMA induces androgen receptor downregulation and cellular apoptosis in prostate cancer cells.
Itsumi M; Shiota M; Yokomizo A; Takeuchi A; Kashiwagi E; Dejima T; Inokuchi J; Tatsugami K; Uchiumi T; Naito S
J Mol Endocrinol; 2014 Aug; 53(1):31-41. PubMed ID: 24780839
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of enhancer of zeste homolog 2 (EZH2) overcomes enzalutamide resistance in castration-resistant prostate cancer.
Bai Y; Zhang Z; Cheng L; Wang R; Chen X; Kong Y; Feng F; Ahmad N; Li L; Liu X
J Biol Chem; 2019 Jun; 294(25):9911-9923. PubMed ID: 31085587
[TBL] [Abstract][Full Text] [Related]
17. Top2a identifies and provides epigenetic rationale for novel combination therapeutic strategies for aggressive prostate cancer.
Kirk JS; Schaarschuch K; Dalimov Z; Lasorsa E; Ku S; Ramakrishnan S; Hu Q; Azabdaftari G; Wang J; Pili R; Ellis L
Oncotarget; 2015 Feb; 6(5):3136-46. PubMed ID: 25605014
[TBL] [Abstract][Full Text] [Related]
18. Scaffold attachment factor B1 regulates the androgen receptor in concert with the growth inhibitory kinase MST1 and the methyltransferase EZH2.
Mukhopadhyay NK; Kim J; You S; Morello M; Hager MH; Huang WC; Ramachandran A; Yang J; Cinar B; Rubin MA; Adam RM; Oesterreich S; Di Vizio D; Freeman MR
Oncogene; 2014 Jun; 33(25):3235-45. PubMed ID: 23893242
[TBL] [Abstract][Full Text] [Related]
19. Collaboration of Kras and androgen receptor signaling stimulates EZH2 expression and tumor-propagating cells in prostate cancer.
Cai H; Memarzadeh S; Stoyanova T; Beharry Z; Kraft AS; Witte ON
Cancer Res; 2012 Sep; 72(18):4672-81. PubMed ID: 22805308
[TBL] [Abstract][Full Text] [Related]
20. ATRA inhibits the proliferation of DU145 prostate cancer cells through reducing the methylation level of HOXB13 gene.
Liu Z; Ren G; Shangguan C; Guo L; Dong Z; Li Y; Zhang W; Zhao L; Hou P; Zhang Y; Wang X; Lu J; Huang B
PLoS One; 2012; 7(7):e40943. PubMed ID: 22808286
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]